Additionally, research suggests that GLP-1 agonists like semaglutide may have an anti-inflammatory effect that can further help lower the risk of heart attack or stroke in people with heart disease and obesity and/or type 2 diabetes
Yes, and you need to understand the reason behind this: In nondiabetic obesity trials , weight loss tends to be larger (especially with tirzepatide or high-dose semaglutide)
Thats why healthcare providers prescribe other semaglultide medications, like Ozempic, to people with Type 2 diabetes to help control their blood sugar levels
The study medication was injected once weekly for 40 weeks
For example, patients taking Mounjaro lost about 17 to 25 pounds on average, while those on semaglutide (such as Ozempic) lost around 13 pounds during clinical trials
Semaglutide is a new medication that has been making headlines for its promising results in weight management and diabetes control